AAM Speaks Out Against Build Back Better Bill
US Pricing Policy Could Unfairly Penalize Generics And Biosimilars Manufacturers
The US Association for Accessible Medicines has panned the Biden administration’s Build Back Better Act, which it says threatens patient access to affordable drugs in its current form.
